...
首页> 外文期刊>Population health management >Treatment and Survival of Medicare Beneficiaries with Colorectal Cancer: A Comparative Analysis Between a Rural State Cancer Registry and National Data
【24h】

Treatment and Survival of Medicare Beneficiaries with Colorectal Cancer: A Comparative Analysis Between a Rural State Cancer Registry and National Data

机译:大肠癌医疗保险受益人的治疗和生存:农村国家癌症登记处和国家数据之间的比较分析

获取原文
获取原文并翻译 | 示例
           

摘要

The aim was to examine and compare with "national'' estimates, receipt of colorectal cancer (CRC) treatment in the initial phase of care and survival following a CRC diagnosis in rural Medicare beneficiaries. A retrospective study was conducted on fee-for-service Medicare beneficiaries diagnosed with CRC in 2003-2006, identified from West Virginia Cancer Registry (WVCR)-Medicare linked database (N = 2119). A comparative cohort was identified from Surveillance, Epidemiology, and End Results (SEER)-Medicare (N = 38,168). CRC treatment received was ascertained from beneficiaries' Medicare claims in the 12 months post CRC diagnosis or until death, whichever happened first. Receipt of minimally appropriate CRC treatment (MACT) was defined using recommended CRC treatment guidelines. All-cause and CRC-specific mortality in the 36-month period post CRC diagnosis were examined. Differences in usage of CRC surgery, chemotherapy, and radiation were observed between the 2 populations, with those from WVCR-Medicare being less likely to receive any type of CRC surgery (adjusted odds ratio [AOR] = 0.82; 95% confidence interval [CI] = [0.73-0.93]). Overall, those from WVCR Medicare had a lower likelihood of receiving MACT, (AOR = 0.85; 95% CI = [0.76-0.96]) compared to their national counterparts. Higher hazard of CRC mortality was observed in the WVCR-Medicare cohort (adjusted hazard ratio = 1.26; 95% CI = [1.20-1.32]) compared to the SEER-Medicare cohort. Although more beneficiaries from WVCR-Medicare were diagnosed in early-stage CRC compared to their SEER-Medicare counterparts, they had a lower likelihood of receiving MACT and a higher hazard of CRC mortality. This study highlights the need for an increased focus on improving access to care at every phase of the CRC care continuum, especially for those from rural settings.
机译:目的是检查并与“全国”估计值进行比较,并与农村医疗保险受益人进行CRC诊断后在护理初期以及在CRC诊断后的生存率对结直肠癌(CRC)的接受程度进行回顾性研究。从西弗吉尼亚癌症登记处(WVCR)-Medidicare链接数据库(N = 2119)确定的2003-2006年被确诊为CRC的Medicare受益人,从监测,流行病学和最终结果(SEER)-Medicare(N = 38,168)。在受益人的CRC诊断后12个月内或直至死亡,以先发生者为准,从受益人的Medicare申领中确定接受的CRC治疗。根据推荐的CRC治疗指南定义了最低限度的CRC治疗(MACT)的接受方式。检查了CRC诊断后36个月内的特定死亡率,观察了这两个人群在CRC手术,化学疗法和放射疗法方面的使用差异。从WVCR-Medicare接受任何类型的CRC手术的可能性较小(调整后的优势比[AOR] = 0.82; 95%置信区间[CI] = [0.73-0.93])。总体而言,与全国同行相比,来自WVCR Medicare的患者接受MACT的可能性更低(AOR = 0.85; 95%CI = [0.76-0.96])。与SEER-Medicare队列相比,在WVCR-Medicare队列中观察到更高的CRC死亡率危险(调整后的危险比= 1.26; 95%CI = [1.20-1.32])。尽管与SEER-Medicare患者相比,WVCR-Medicare患者在CRC早期被诊断出更多的受益者,但他们接受MACT的可能性更低,CRC死亡率更高。这项研究强调,有必要在CRC护理连续性的每个阶段,尤其是农村地区的护理方面,更加注重改善获得护理的机会。

著录项

  • 来源
    《Population health management》 |2017年第1期|55-65|共11页
  • 作者单位

    Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, Boston, MA USA;

    West Virginia Univ, Dept Pharmaceut Syst & Policy, Sch Pharm, Morgantown, WV USA;

    West Virginia Univ, Dept Pharmaceut Syst & Policy, Sch Pharm, Morgantown, WV USA;

    West Virginia Univ, Dept Pharmaceut Syst & Policy, Sch Pharm, Morgantown, WV USA;

    West Virginia Univ, Dept Radiol Hematol Oncol, Mary Babb Randolph Canc Ctr, Morgantown, WV USA;

    Evidera, Lexington, MA USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号